Atherosclerotic disease and risk factor modification in Saudi Arabia: A call to action

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 349-355

  Al Omran, Mohammed ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Atherosclerosis; Coronary artery disease; Peripheral arterial disease; Risk reduction

Indexed keywords

ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT;

ADULT; ARTICLE; ATTITUDE TO ILLNESS; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NICOTINE REPLACEMENT THERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICIAN ATTITUDE; RISK FACTOR; RISK REDUCTION; SAUDI ARABIA; SMOKING; TREATMENT INDICATION; ATTITUDE TO HEALTH; AWARENESS; BLOOD; BODY MASS; CARDIOVASCULAR DISEASE; CHI SQUARE DISTRIBUTION; CLINICAL COMPETENCE; CLINICAL PRACTICE; HEALTH PERSONNEL ATTITUDE; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; QUESTIONNAIRE; RISK ASSESSMENT; SMOKING CESSATION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATTITUDE OF HEALTH PERSONNEL; AWARENESS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; CLINICAL COMPETENCE; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SAUDI ARABIA; SMOKING; SMOKING CESSATION;

EID: 84867678816     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S32783     Document Type: Article

References (27)

1. Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135(4):331-340.
2. World Health Report 2010 [report on the Internet]. What is the deadliest disease in the world? Geneva: World Health Organization; 2010 [updated October 20, 2010; cited March 15, 2012]. Available from: http://www.who.int/features/qa/18/en/. Accessed March 15, 2012.
3. World Health Report 2010 [report on the Internet]. Causes of mortality in Saudi Arabia. Geneva: World Health Organization; 2011 [updated 2011; cited March 15, 2012]. Available from: http://www.who.int/nmh/countries/sau_en.pdf. Accessed March 15, 2012.
4. Al-Nozha MM, Arafah MR, Al-Mazrou YY, et al. Coronary artery disease in Saudi Arabia. Saudi Med J. 2004;25(9): 1165-1171.
5. Al-Sheikh SO, Aljabri BA, Al-Ansary LA, Al-Khayal LA, Al-Salman MM, Al-Omran MA. Prevalence of and risk factors for peripheral arterial disease in Saudi Arabia. A pilot cross-sectional study. Saudi Med J. 2007;28(3):412-414.
6. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381-386.
7. Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol. 1992;49(8): 857-863.
8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038): 1329-1339.
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329):71-86.
10. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3): 145-153.
11. Heart Protection Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 highrisk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
12. Grover SA, Gray-Donald K, Joseph L, Abrahamowicz M, Coupal L. Life expectancy following dietary modification or smoking cessation. Estimating the benefits of a prudent lifestyle. Arch Intern Med. 1994; 154(15):1697-1704.
13. American Diabetes Association. Position Statement. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25:S33-S49.
14. Hirsch AT, Haskal ZJ, Hertzer NR, et al; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter- Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463-e654.
15. Abramson BL, Huckell V, Anand S, et al. Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease-executive summary. Can J Cardiol. 2005;21(12):997-1006.
16. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372.
17. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458-2473.
18. McDermott MM, Hahn EA, Greenland P, et al. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J Gen Intern Med. 2002;17(12):895-904.
19. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317-1324.
20. Hirsch AT, Gloviczki P, Drooz A, Lovell M, Creager MA. Mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health. J Vasc Surg. 2004;39(2):474-481.
21. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-189.
22. Cassar K, Belch JJ, Brittenden J. Are national cardiac guidelines being applied by vascular surgeons? Eur J Vasc Endovasc Surg. 2003;26(6):623-628.
23. Al-Omran M, Lindsay TF, Major J, Jawas A, Leiter LA, Verma S. Perceptions of Canadian vascular surgeons toward pharmacological risk reduction in patients with peripheral arterial disease. Ann Vasc Surg. 2006;20(5):555-563.
24. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ. 2004;171(10):1189-1192.
25. Al-Omran M. Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease. Vasc Health Risk Manag. 2007;3(6):1019-1027.
26. Mukherjee D, Lingam P, Chetcuti S, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation. 2002;106(15):1909-1912.
27. McDermott MM, Mandapat AL, Moates A, et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med. 2003;163(18):2157-2162.